Derek DiRocco, Ph.D.

Derek DiRocco is a member of the board of directors of Evommune since October 2024 and is a Partner at RA Capital Management. Derek works on both public and private investments and serves as a member of the board of directors for 89Bio, Mineralys, Werewolf Therapeutics, Acrivon Therapeutics, Rivus Pharmaceuticals, , Forward Therapeutics and Sera Medicines. Derek joined RA Capital in July 2013 and initially covered solid tumor oncology landscapes, later broadening coverage to multiple therapeutic areas. Derek holds a B.A. in Biology from Holy Cross College and a Ph.D. in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched signaling pathways responsible for chronic and acute kidney disease, as well as cellular mechanisms underlying fibrotic disease.